Newsfilter article unlocker

Enter Newsfilter article ID in the field below.
Example: https://newsfilter.io/articles/39be1bef03e66cdc886c08a2a6319c47

Retrieved article

Hims & Hers Health (HIMS.N) raised its 2026 revenue ​forecast on Monday, betting ‌on increased sales for its personalized healthcare offerings.

The company now expects ​annual revenue between $2.8 billion ​and $3 billion, compared with its previous ⁠forecast of $2.7 billion to $2.9 ​billion.

In March, Hims said it would ​partner with Novo Nordisk (NOVOb.CO) to offer its blockbuster weight-loss drug, Wegovy, on ​its platform, ending a legal ​dispute between the companies.

The dispute had ‌followed ⁠Hims' launch of a low-cost compounded alternative to Wegovy, which it has since discontinued.

Hims expects ​second-quarter revenue ​in ⁠the range of $680 million to $700 million, compared with ​analysts' average estimate of $642.95 ​million, ⁠according to data compiled by LSEG.

Shares of the company were ⁠down ​6% at $27.20 in ​after-market trading.


...